Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29985009 | 1.00 | TP53 (0.50) | TP53TDP1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL28967049 | 0.88 | CYP3A4 (0.47) | TP53TDP1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL232779 | 0.81 | TP53 (0.64) | TP53TDP1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL29944162 | 0.81 | CYP3A4 (0.65) | TP53TDP1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL132541 | 0.81 | CYP3A4 (0.65) | TP53TDP1CYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL816365 | 0.81 | CYP19A1 (0.48) | TDP1CYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9312899 | 0.81 | CYP19A1 (0.54) | TDP1CYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28967010 | 0.81 | ATM (0.51) | TP53CYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1635708 | 0.81 | HTT (0.50) | SMN1; SMN2MEN1KMT2AALOX5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3088495 | 0.79 | TP53 (0.62) | TP53TDP1CYP3A4SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803316-A | Pyridone compound and preparation method and application thereof | 深圳晶泰科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-111454186-B | Aryl formanilide compound containing pentafluorothio and preparation method and application thereof | 山东省联合农药工业有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-111454202-B | Heteroaryl formanilide compound containing pentafluorothio and preparation method and application thereof | 山东省联合农药工业有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-111454202-A | Heteroaryl formanilide compound containing pentafluorothio and preparation method and application thereof | 山东省联合农药工业有限公司 | 2020-07-28 | — | — | CN | disclosed |
| CN-111454186-A | Aryl formanilide compound containing pentafluorothio and preparation method and application thereof | 山东省联合农药工业有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-3207038-B1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | Bayer Pharma AG (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-9884849-B2 | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9884849-B2 | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20170217938-A1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217938-A1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-7863269-B2 | protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants | SANOFI-AVENTIS (FR) | 2011-01-04 | — | — | US | disclosed |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-07-30 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317124-B2 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20050148652-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148652-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | PFAS, DDT, PNPO | TP53 3117/4885TDP1 2863/4885CYP3A4 29/4885 |
| US-20170217938-A1 | FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | DHFR, FANCF, FANCI | TP53 625/4885TDP1 557/4885CYP3A4 1001/4885 |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | F2R, TFPI, F2RL1 | TP53 4528/4885TDP1 760/4885CYP3A4 152/4885 |
| US-20080091031-A1 | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates | PFAS, DDT, PNPO | TP53 3117/4885TDP1 2863/4885CYP3A4 29/4885 |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL1, F2RL3 | TP53 2149/4885TDP1 620/4885CYP3A4 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.